User login
Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.
Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).
Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.
Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.
Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.
Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.
Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).
Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.
Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.
Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.
Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.
Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).
Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.
Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.
Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.